TTLL12

Across TCGA pan-cancer cohorts, TTLL12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TTLL12 data layer compared with 30 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TTLL12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTLL12 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LIHC, SKCM, and UCEC are the cancer types where TTLL12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.047	0.556	<.001	24	view →
SKCM	OS	Median	All	0.225	0.788	<.001	23	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
CESC	OS	Median	All	0.124	0.588	.037	6	view →
STAD	DFS	Median	III,IV	1.000	0.312	.040	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TTLL12–LIHC (DFS)

Open the LIHC breakdown →